Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Arvinas, Inc. (NASDAQ:ARVN) shares fell sharply by 29% as the market reacted to the company’s announcement of a significant workforce reduction and the removal of two Phase 3 trials from its ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...

Arvinas (NASDAQ:ARVN) is scheduled to announce Q1 earnings results on Thursday, May 1st, before market open. The consensus ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical ...

Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American ...

Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – ...

And M.2 drivers offer the best possible combination of speed, size, and performance. Also: The best network-attached storage devices you can buy Now that these storage drives have been around for ...